What does the D614G mutation mean for COVID-19?
Recently, a research article titled Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant was published in Cell. Scientists studied the D614G mutation from different aspects of cell biology and structural biology. The details were summarized in our R&D article.
Currently, almost 200 COVID-19 vaccine development projects are going on. When evaluating the efficacy of the vaccine, scientists usually use spike protein or receptor binding domains to measure the antibody titer. It is worth mentioning that Moderna used D614G spike protein instead in these assays.[1]
ACROBiosystems developed a few stable recombinant spike trimer protein products including D614G spike trimer protein, ancestral D614G spike trimer protein as well as related protein-coupled magnetic beads, which are all designed for COVID-19 therapeutic and vaccine development.
Product List
Assay Data
Fig 1. The purity of SARS-CoV-2 S protein (D614G), His Tag, Super stable trimer (Cat. No. SPN-C52H3) was more than 90% and the molecular weight of this protein is around 520-620 kDa verified by SEC-MALS.
Fig 2. Immobilized Human ACE2, Fc Tag (Cat. No. AC2-H5257) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 S protein (D614G), His Tag, Super stable trimer (Cat. No. SPN-C52H3) with a linear range of 0.2-5 ng/mL.